GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (NYSE:DVA) » Definitions » Net Change in Cash

DVA (DaVita) Net Change in Cash : $94 Mil (TTM As of Mar. 2025)


View and export this data going back to 1995. Start your Free Trial

What is DaVita Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

DaVita's Net Change in Cash for the three months ended in Mar. 2025 was $-355 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 was $94 Mil.

DaVita Net Change in Cash Historical Data

The historical data trend for DaVita's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

DaVita Net Change in Cash Chart

DaVita Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -706.93 53.17 -215.97 125.65 415.19

DaVita Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -33.85 72.47 655.40 -278.82 -355.25

DaVita Net Change in Cash Calculation

DaVita's Net Change in Cash for the fiscal year that ended in Dec. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=2022.038+-771.429+-816.937+-18.481
=415

DaVita's Net Change in Cash for the quarter that ended in Mar. 2025

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=180.009+-162.138+-382.54+9.417
=-355

Net Change in Cash for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $94 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

DaVita Net Change in Cash Related Terms

Thank you for viewing the detailed overview of DaVita's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

DaVita Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » DaVita Inc (NYSE:DVA) » Definitions » Net Change in Cash
Comparable Companies
UHS EHC ENSG CHE THC OPCH AMED SGRY CON ADUS HCA XTER:FRE SAU:4013 XTER:FME SZSE:300015 BOM:543220 BSP:RDOR3 XKLS:5225 NSE:APOLLOHOSP BKK:BDMS
Traded in Other Exchanges
0I7E:UK TRL:Germany TRL:Germany DVAI34:Brazil
Address
2000 16th Street, Denver, CO, USA, 80202
Website
https://www.davita.com
DaVita is the largest provider of dialysis services in the United States, boasting market share of about 35% when measured by clinics. The firm operates over 3,000 facilities worldwide, mostly in the US, and treats about 280,000 patients globally each year. Government payers dominate US dialysis reimbursement. DaVita receives about two thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business. Berkshire Hathaway owns about 45% of DaVita.
Executives
Berkshire Hathaway Inc 10 percent owner 3555 FARNAM STREET, OMAHA NE 68131
Javier Rodriguez officer: Chief Executive Officer, DKC 601 HAWAII ST., EL SEGUNDO CA 90245
Joel Ackerman officer: Chief Financial Officer COVENTRY HEALTH CARE, INC., 6705 ROCKLEDGE DR SUITE 900, BETHESDA MD 20817
Michael David Staffieri officer: Chief Operating Officer, DKC 2000 16TH STREET, DENVER CO 80202
Kathleen Alyce Waters officer: Chief Legal Officer C/O DAVITA INC., 2000 16TH STREET, DENVER CO 80202
Barbara J Desoer director CITIGROUP INC., 388 GREENWICH STREET, 17TH FLOOR, NEW YORK NY 10013
James O Hearty officer: Chief Compliance Officer 2000 16TH STREET, DENVER CO 80202
Christopher Michael Berry officer: Chief Accounting Officer C/O SONDER HOLDINGS INC., 101 15TH ST., SAN FRANCISCO CA 94103
Wendy Lee Schoppert director 6105 TRENTON LANE NORTH, MINNEAPOLIS MN 55442
Phyllis R Yale director
Charles Berg director, officer: Executive Chair, DMG 48 MONROE TURNPIKE, TRUMBULL CT 06611
John M Nehra director 1119 ST PAUL ST, BALTIMORE MD 21202
Adam H Schechter director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Jason M. Hollar director 3333 BEVERLY ROAD, HOFFMAN ESTATES IL 60179
Paula A Price director ONE CVS DRIVE, WOONSOCKET RI 02895